argenx (ARGX) Scheduled to Post Earnings on Thursday

argenx (NASDAQ:ARGX) will be issuing its quarterly earnings data before the market opens on Thursday, October 31st. Analysts expect the company to announce earnings of $0.10 per share for the quarter.

argenx Price Performance

NASDAQ:ARGX opened at $552.88 on Wednesday. The company’s 50-day moving average is $536.03 and its two-hundred day moving average is $462.82. The firm has a market capitalization of $32.86 billion, a price-to-earnings ratio of -97.68 and a beta of 0.63. argenx has a 1-year low of $327.73 and a 1-year high of $571.97.

Analyst Ratings Changes

Several equities research analysts have issued reports on ARGX shares. Deutsche Bank Aktiengesellschaft cut argenx from a “buy” rating to a “hold” rating in a research note on Friday, October 4th. Wells Fargo & Company boosted their price target on shares of argenx from $543.00 to $547.00 and gave the company an “overweight” rating in a research note on Friday, July 26th. Oppenheimer raised shares of argenx from a “market perform” rating to an “outperform” rating and set a $546.00 price objective for the company in a research report on Tuesday, July 23rd. HC Wainwright boosted their target price on argenx from $504.00 to $533.00 and gave the company a “buy” rating in a research report on Friday, July 26th. Finally, Barclays upgraded argenx from an “equal weight” rating to an “overweight” rating in a research report on Tuesday, August 6th. Four investment analysts have rated the stock with a hold rating, seventeen have issued a buy rating and one has given a strong buy rating to the company’s stock. According to data from MarketBeat, argenx has an average rating of “Moderate Buy” and an average target price of $550.44.

argenx Company Profile

argenx SE, a biotechnology company, engages in the developing of various therapies for the treatment of autoimmune diseases in the United States, Japan, Europe, Middle East, Africa, and China. Its lead product candidate is efgartigimod for the treatment of patients with myasthenia gravis, immune thrombocytopenia, pemphigus vulgaris, generalized myasthenia gravis, chronic inflammatory demyelinating polyneuropathy, thyroid eye disease, bullous pemphigoid, myositis, primary sjögren’s syndrome, post-covid postural orthostatic tachycardia syndrome, membranous nephropathy, lupus nephropathy, anca-associated vasculitis, and antibody mediated rejection; ENHANZE SC; Empasiprubart for multifocal motor neuropath, delayed graft function, and dermatomyositis; and ARGX-119 for congenital myasthenic syndrome and amyotrophic lateral sclerosis.